Quick Answer
GYRE THERAPEUTICS, INC. reported Cash And Cash Equivalents At Carrying Value of $37.07 million for the year ending 2025.
- GYRE THERAPEUTICS, INC. showed an increase of +213.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from GYRE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), GYRE THERAPEUTICS, INC.'s Cash And Cash Equivalents At Carrying Value has declined by 27.6%.
- Historical annual values: Fiscal year 2025: $37.07 million | Fiscal year 2024: $11.81 million | Fiscal year 2023: $33.51 million | Fiscal year 2022: $25.18 million | Fiscal year 2021: $44.35 million | Fiscal year 2020: $30.36 million | Fiscal year 2019: $15.37 million | Fiscal year 2018: $31.21 million | Fiscal year 2017: $14.47 million | Fiscal year 2016: $10.26 million | Fiscal year 2015: $29.10 million | Fiscal year 2014: $1.54 million | Fiscal year 2013: $2.83 million | Fiscal year 2012: $3.40 million | Fiscal year 2011: $107.28 million | Fiscal year 2010: $165.85 million | Fiscal year 2009: $83.91 million | Fiscal year 2008: $51.20 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: